SAM
CYTK icon

Shell Asset Management’s Cytokinetics CYTK Stock Holding History

Shell Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-41,875
Closed -$607K – 1110
2017
Q3 		$607K Sell
41,875
-1,000
-2% -$13.7K 0.01% 792
2017
Q2 		$519K Hold
42,875
– – 0.01% 895
2017
Q1 		$551K Buy
+42,875
New +$501K 0.01% 861

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Shell Asset Management's CYTK Position: Q4 2017 in Review

Shell Asset Management sold out of Cytokinetics (CYTK) in Q4 2017, closing a stake of 41,875 shares — an estimated $607K sold.

Shell Asset Management first reported a position in CYTK in Q1 2017 and held it in 3 quarters. The position peaked at $607K in Q3 2017. 134 funds tracked by Wall St. Rank hold CYTK as of Q4 2017.

  • Shell Asset Management reported no remaining Cytokinetics position as of Q4 2017 after selling out during the quarter.
  • Shell Asset Management sold 41,875 Cytokinetics shares in Q4 2017, an estimated $607K.
  • Shell Asset Management first reported a position in Cytokinetics in Q1 2017 and held it in 3 quarters.
  • Shell Asset Management's Cytokinetics position peaked at $607K in Q3 2017.
  • 134 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2017.

Based on Shell Asset Management's 13F filing for Q4 2017, filed 9 Feb 2018.